Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Procedure: Magnetic Resonance ImagingRadiation: Photon Beam Radiation TherapyOther: Questionnaire Administration
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 306
- Registration Number
- NCT05095376
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
- Conditions
- Recurrent GliosarcomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Emory University
- Registration Number
- NCT05017610
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
- Conditions
- First Progression of MGMT Promoter-methylated Glioblastoma
- Interventions
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭UniversitaetsSpital, Zürich, Switzerland
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 25
- Registration Number
- NCT04863950
- Locations
- 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme, Adult
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- CNS Pharmaceuticals, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT04762069
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 142
- Registration Number
- NCT04573192
- Locations
- 🇩🇪
Klinikum rechts der Isar, München, Germany
🇩🇪University Hospital Köln, Köln, Germany
🇫🇷Hôpital Saint Louis, Paris, France
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation: Standard Fractionated Radiation therapy (RT)Device: TTField
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04421378
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, California, United States
🇺🇸University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
- Conditions
- Medulloblastoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-08-26
- Target Recruit Count
- 20
- Registration Number
- NCT04402073
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇦🇺Austin Health - Austin hospital, Melbourne, Australia
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
- Conditions
- GlioblastomaMedulloblastomaEpendymomaDiffuse Intrinsic Pontine Glioma
- Interventions
- Radiation: Partial RadiationRadiation: Full-dose Radiation
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Theodore S. Johnson
- Target Recruit Count
- 140
- Registration Number
- NCT04049669
- Locations
- 🇺🇸
Augusta University, Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸Emory University, Children's Heathcare of Atlanta, Druid Hills, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Global Coalition for Adaptive Research
- Target Recruit Count
- 1030
- Registration Number
- NCT03970447
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸St. Joseph Hospital, Orange, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.